Abstract 2439
Background
Tumour infiltrating T cell subsets are associated with a prognosis in gastric cancer (GC). However, there has been no study of T cell subsets on the efficacy of immune checkpoint blockades (ICBs). This study was designed to assess T cell subsets in tumour by using multiplex immunohistochemistry (mIHC) and to evaluate the association of T cell subsets and efficacy of ICBs in patients with GC who received ICBs.
Methods
We assess patients who have treated with ICBs and available tumour tissues before initiation of ICBs. Multiple stainings were performed with different kinds of T cell or immune checkpoint surface markers (CD3, CD4, CD8, PD-L1, PD1, FOXP3, CK, Ki-67, TIM-3, LAG-3, CD45 and CD45RO) in a single section through 12 times-repeated staining-scanning-stripping procedures. Density was defined to be the number of positively-stained cells per mm2.
Results
Eighty-four patients (40 (47.6%) in first- or second-line; 44 (52.4%) in third- or later lines) were analyzed. Patients with MSI-H, EBV and non-MSI/non-EBV were 7 (8.3%), 3 (3.6%) and 74 (88.1%). A high intratumoral CD3+CD8+/CD3+ T cells ratio was associated with better response rate (RR) (34.2% vs 8.8%, p = 0.034) and longer overall survival (OS) (24.3 vs. 5.9 months, p < 0.001). A high CD3+CD8+ density (17.9 vs. 5.9 months, p = 0.001), high stromal CD3+CD4+FOXP3+/CD3+CD4+ T cells ratio (5.5 vs. 2.5 months, p = 0.0001, in PFS), low CD3+CD4+/CD3+ T cells ratio (5.7 vs. 24.3 months, p < 0.001) and low CD3+CD45RO+/CD3+ T cells ratio (7.1 vs. 10.4 months, p = 0.033) were correlated with improved OS. Low CD3+CD4+/CD3+ T cells ratio (33.3% vs. 9.1%, p = 0.041) and high stromal CD3+CD4+Foxp3+/CD3+CD4+ T cells ratio (37.8% vs. 5.7%, p = 0.004) were significantly associated with better tumor response. GC harboring MSI-H and EBV had higher CD3+C8+/CD3+ cells ratio and CD3+CD8+ T cells density than GC with non-MSI/non EBV. Patients with MSI-H and EBV had longer OS than those with non-MSI/non-EBV (not reached to median value, 27.3 months and 7.0 months, p < 0.001).
Conclusions
Composition, density and distribution of T cell subsets in tumour were associated with the response to ICBs. mIHC is a good method to assess T cell subsets in archival tumour tissue.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Seoul National University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
870 - Selective Wnt/β-catenin small-molecule inhibitor CWP232228 impairs tumor growth of colon cancer
Presenter: Jin Young Kim
Session: Poster Display session 2
Resources:
Abstract
3425 - Feasibility and impact of prospective DPYD screening in the Irish population
Presenter: Mohammed Zameer
Session: Poster Display session 2
Resources:
Abstract
1972 - Diet-derived metabolites and the risk of colorectal cancer: a nested case-control study in a population-based cohort, the Singapore Chinese Health Study
Presenter: Dawn Chong
Session: Poster Display session 2
Resources:
Abstract
4103 - Loss of subcutaneous adipose tissue during chemotherapy predicts reduced survival in patients with incurable colorectal cancer undergoing palliative therapy
Presenter: Erin Stella Sullivan
Session: Poster Display session 2
Resources:
Abstract
4309 - Obese and overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab.
Presenter: Bozena Cybulska-Stopa
Session: Poster Display session 2
Resources:
Abstract
3554 - Patient characteristics associated with poor performance status, ECOG 2-3, and effect on survival in 1086 Finnish metastatic colorectal cancers (mCRC) nationwide (prospective RAXO study)
Presenter: Pia Österlund
Session: Poster Display session 2
Resources:
Abstract
4572 - Discovery and Diagnosis of Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results from a European Survey
Presenter: Iga Rawicka
Session: Poster Display session 2
Resources:
Abstract
4783 - Adherence to recommended intake of calcium and colorectal cancer risk in the HEXA study
Presenter: Jeeyoo Lee
Session: Poster Display session 2
Resources:
Abstract
5106 - Body size, sex and sidedness of incident colorectal cancer in a prospective Swedish cohort study
Presenter: Christina Siesing
Session: Poster Display session 2
Resources:
Abstract
3364 - Middle East & North Africa Registry to characterize RAS mutation status and tumor specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)
Presenter: Mohamed Oukkal
Session: Poster Display session 2
Resources:
Abstract